Replies to post #172743 on Biotech Values

[mcbio]

In this particular case, if you don't think Drisapersen even works at least for some patients, there really isn't much reason besides EU patent to hold RNA as rest of their pipelines use similar approaches.

I respectfully disagree as RNA has said the follow-on drugs are much more efficient at exon skipping than drisapersen (~3x) and they believe this will translate into better efficacy. Of course, this still has to be proven in the clinic but at least they have a rationale as to why the follow-on drugs may work better.